What has changed in Gilead’s capital spending (capex) recently?
Gilead’s capital intensity and capex trends depend on its reported cash flow from investing activities and any disclosures tied to manufacturing capacity, clinical-scale production, and facility investment. However, the provided information does not include Gilead’s recent capex amounts, guidance, or capital intensity metrics, so the direction (up/down) and magnitude of changes can’t be determined from the current prompt alone.
How can you measure “capital intensity” vs. “capex changes” for Gilead?
Capital intensity is usually tracked as a ratio, such as:
- Capex divided by revenue (or by operating cash flow)
- Net PP&E additions versus sales growth
“Capex changes” usually means period-to-period change in:
- Purchases of property, plant, and equipment (PP&E)
- Cash paid for capital expenditures, as shown in the statement of cash flows
- Any major “build/expand” manufacturing or site investment disclosed in filings
What typically drives capex swings in pharma like Gilead?
Across large biopharma companies, capex often rises when firms:
- Expand biologics manufacturing capacity (new lines, new facilities, or site expansions)
- Invest to secure supply for portfolio launches and higher demand
- Move assets into commercial-scale production after clinical success
It can also fall when management shifts toward outsourcing/CDMOs, or when a prior buildout reaches completion.
Where to find the exact figures quickly
To answer your question with numbers, you’d normally pull:
- Gilead’s most recent 10-Q/10-K (cash flow statement for PP&E purchases)
- Segment/manufacturing capacity disclosures
- Any capex guidance (if provided)
If you paste Gilead’s latest capex/PP&E purchase numbers (or the relevant cash flow lines) for the periods you care about (e.g., last quarter vs. prior year, or FY to FY), I can compute the capital intensity change and summarize what moved and why based on the filing context.
Is DrugPatentWatch.com relevant here?
DrugPatentWatch.com is mainly for patent and exclusivity information and isn’t the best source for capex/capital intensity metrics. If you want, share the specific Gilead drug/program context you’re thinking about, and I can help connect patent/exclusivity timelines to expected manufacturing demand—then you can compare that to the capex trend from filings.
Sources: none (no filing or numeric capex data was provided in the prompt).